Skip to content

King & Wood Mallesons Pulse

  • Topics
    • All Topics
    • Carbon markets
    • Competition & consumer
    • Consumer protection
    • ESG
    • Future energy
    • Hydrogen
    • Inhouse Counsel
    • International Arbitration
    • Intellectual Property
    • Technology
  • Jurisdictions
    • Australia
    • China
    • Hong Kong
    • Singapore
    • Global
  • Specialty Blogs
    • In Competition
    • International Arbitration
    • IP Whiteboard
  • Authors

King & Wood Mallesons Pulse

  • Topics
    • All Topics
    • Carbon markets
    • Competition & consumer
    • Consumer protection
    • ESG
    • Future energy
    • Hydrogen
    • Inhouse Counsel
    • International Arbitration
    • Intellectual Property
    • Technology
  • Jurisdictions
    • Australia
    • China
    • Hong Kong
    • Singapore
    • Global
  • Specialty Blogs
    • In Competition
    • International Arbitration
    • IP Whiteboard
  • Authors

medicine

Fast drugs, new drugs: new opportunities in the healthcare industry in Australia and China

Fast drugs, new drugs: new opportunities in the healthcare industry in Australia and China

27 April 2018
By Suzy Madar
Chinese and Australian businesses looking for overseas opportunities to expand in the healthcare industry should be aware of important regulatory changes that are taking place in both China and Australia.
Read on

Speciality Blogs

  • In Competition
  • International Arbitration
  • IP Whiteboard

More From IP Whiteboard

  • IP Whiteboard

Trending Topics

  • Dispute resolution & litigation
  • Hong Kong
  • Litigation
  • Technology
View All Topics

Most Viewed

Bilateral relations for Australia & China enter a new chapter

Read More

ASIC flexes muscles in scam and phishing takedowns

Read More
King & Wood Mallesons
©2025 King & Wood Mallesons

Follow Us

  • LinkedIn
  • Facebook
  • Twitter
Subscribe to KWM Pulse
Terms of use & legal notices | Privacy statement
©2025 King & Wood Mallesons